Seguir
Andrea Rosario Beccari
Andrea Rosario Beccari
Head EXSCALATE Platform, Dompe Farmaceutici SpA
Email confirmado em usa.net
Título
Citado por
Citado por
Ano
ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets
C Bizzarri, AR Beccari, R Bertini, MR Cavicchia, S Giorgini, M Allegretti
Pharmacology & therapeutics 112 (1), 139-149, 2006
2562006
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
S Günther, PYA Reinke, Y Fernández-García, J Lieske, TJ Lane, HM Ginn, ...
Science 372 (6542), 642-646, 2021
1522021
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2
A Moriconi, MC Cesta, MN Cervellera, A Aramini, S Coniglio, S Colagioia, ...
Journal of medicinal chemistry 50 (17), 3984-4002, 2007
1032007
Targeting C5a: recent advances in drug discovery
M Allegretti, A Moriconi, AR Beccari, RD Bitondo, C Bizzarri, R Bertini, ...
Current medicinal chemistry 12 (2), 217-236, 2005
1012005
Combining molecular modeling with experimental methodologies: mechanism of membrane permeation and accumulation of ofloxacin
M Fresta, S Guccione, AR Beccari, PM Furneri, G Puglisi
Bioorganic & medicinal chemistry 10 (12), 3871-3889, 2002
932002
Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities
R Cannalire, C Cerchia, AR Beccari, FS Di Leva, V Summa
Journal of medicinal chemistry 65 (4), 2716-2746, 2020
892020
Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non‐competitive allosteric inhibitor
R Bertini, LS Barcelos, AR Beccari, B Cavalieri, A Moriconi, C Bizzarri, ...
British journal of pharmacology 165 (2), 436-454, 2012
642012
PARP1-produced poly-ADP-ribose causes the PARP12 translocation to stress granules and impairment of Golgi complex functions
G Catara, G Grimaldi, L Schembri, D Spano, G Turacchio, M Lo Monte, ...
Scientific reports 7 (1), 1-17, 2017
632017
Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief
A Moriconi, TM Cunha, GR Souza, AH Lopes, FQ Cunha, VL Carneiro, ...
Proceedings of the National Academy of Sciences 111 (47), 16937-16942, 2014
622014
SARS-CoV-2 entry inhibitors: Small molecules and peptides targeting virus or host cells
R Cannalire, I Stefanelli, C Cerchia, AR Beccari, S Pelliccia, V Summa
International Journal of Molecular Sciences 21 (16), 5707, 2020
592020
LiGen: a high performance workflow for chemistry driven de novo design
AR Beccari, C Cavazzoni, C Beato, G Costantino
Journal of chemical information and modeling 53 (6), 1518-1527, 2013
562013
Identification of inhibitors of SARS-CoV-2 3CL-pro enzymatic activity using a small molecule in vitro repurposing screen
M Kuzikov, E Costanzi, J Reinshagen, F Esposito, L Vangeel, M Wolf, ...
ACS pharmacology & translational science 4 (3), 1096-1110, 2021
482021
Computational studies of SARS-CoV-2 3CLpro: Insights from MD simulations
A Grottesi, N Bešker, A Emerson, C Manelfi, AR Beccari, F Frigerio, ...
International journal of molecular sciences 21 (15), 5346, 2020
462020
Auto-regulation of secretory flux by sensing and responding to the folded cargo protein load in the endoplasmic reticulum
A Subramanian, A Capalbo, NR Iyengar, R Rizzo, A di Campli, ...
Cell 176 (6), 1461-1476. e23, 2019
462019
The ANTAREX approach to autotuning and adaptivity for energy efficient HPC systems
C Silvano, G Agosta, S Cherubin, D Gadioli, G Palermo, A Bartolini, ...
Proceedings of the ACM International Conference on Computing Frontiers, 288-293, 2016
432016
Molecular mechanism and functional role of brefeldin A-mediated ADP-ribosylation of CtBP1/BARS
A Colanzi, G Grimaldi, G Catara, C Valente, C Cericola, P Liberali, ...
Proceedings of the National Academy of Sciences 110 (24), 9794-9799, 2013
392013
Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls
M Allegretti, R Bertini, C Bizzarri, A Beccari, A Mantovani, M Locati
Trends in pharmacological sciences 29 (6), 280-286, 2008
372008
Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring
F Oger, A Lecorgne, E Sala, V Nardese, F Demay, S Chevance, ...
Journal of medicinal chemistry 53 (5), 1937-1950, 2010
342010
Use of experimental design to optimize docking performance: The case of ligendock, the docking module of ligen, a new de novo design program
C Beato, AR Beccari, C Cavazzoni, S Lorenzi, G Costantino
Journal of chemical information and modeling 53 (6), 1503-1517, 2013
322013
A blueprint for high affinity SARS-CoV-2 Mpro inhibitors from activity-based compound library screening guided by analysis of protein dynamics
J Gossen, S Albani, A Hanke, BP Joseph, C Bergh, M Kuzikov, E Costanzi, ...
ACS pharmacology & translational science 4 (3), 1079-1095, 2021
272021
O sistema não pode efectuar a operação agora. Tente mais tarde.
Artigos 1–20